Furthermore, another successful human treatment with anti-CD19 CAR-T therapy has been reported for treating another autoimmune disease, myasthenia gravis, caused by a B-cell-driven dysfunction of neuromuscular transmission, often mediated by anti-acetylcholine receptor (anti-AchR) antibodies. This evidence concerns the gene CD19 and autoimmune disease.